{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.27","upperLimit":"8.34","value":"5.59"},{"groupId":"OG001","lowerLimit":"2.99","upperLimit":"13.86","value":"5.55"},{"groupId":"OG002","lowerLimit":"5.29","upperLimit":"10.74","value":"6.90"},{"comment":"Unable to estimate due to low numbers.","groupId":"OG003","lowerLimit":"2.99","upperLimit":"NA","value":"4.21"},{"comment":"Unable to estimate due to low numbers.","groupId":"OG004","lowerLimit":"7.20","upperLimit":"NA","value":"11.24"},{"groupId":"OG005","lowerLimit":"2.79","upperLimit":"4.21","value":"3.29"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"description":"Duration of objective response was defined as the time from the tumor assessment that first documented PR or CR that was subsequently confirmed at least 28 days later until the date of documented progression. There were either few or no responders in the Gastric/GEJ, SCLC, and pancreatic cohorts so these cohorts are excluded.","dispersionType":"95% Confidence Interval","groups":[{"description":"cabozantinib, 100 mg, po QD ongoing until progression","id":"OG000","title":"CRPC"},{"description":"cabozantinib, 100 mg, po QD ongoing until progression","id":"OG001","title":"Melanoma"},{"description":"cabozantinib, 100 mg, po QD ongoing until progression","id":"OG002","title":"NSCLC"},{"description":"cabozantinib, 100 mg, po QD ongoing until progression","id":"OG003","title":"Hepatocellular Carcinoma"},{"description":"cabozantinib, 100 mg, po QD ongoing until progression","id":"OG004","title":"Ovarian Cancer"},{"description":"cabozantinib, 100 mg, po QD ongoing until progression","id":"OG005","title":"Metastatic Breast Cancer"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From initial dose through final study visit up to 44 months","title":"Duration of Objective Response (OR) - Responders From Lead-in Stage","type":"SECONDARY","unitOfMeasure":"Months"}